MustGrow Biologics Corp. is set to report its earnings on June 2, 2026, and investors are eagerly awaiting insights after a tough fiscal year. With an EPS estimate of -CA$0.02, the company’s performance will be closely watched for signs of recovery.
Scheduled for release after the market closes on June 2, 2026, MustGrow Biologics Corp. will provide its earnings report for the fiscal period ending March 31, 2026. Analysts expect an EPS of -CA$0.02, which could indicate ongoing struggles as the company works on its growth strategy in the U.S. market. This report comes after significant developments, including the closure of its Canadian distribution arm and the recent approval of its TerraSante™ product in Georgia.
Investor takeaway: Long-term investors should monitor MustGrow's earnings for signs of strategic effectiveness and market adaptation, especially in the U.S.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
MustGrow Biologics Corp.
MGRO.V
MGRO.V
MustGrow Biologics Corp.
WealthAwesomeMarket cap
$27.46M
52W high
$0.94
52W low
$0.31
1W change
+13.43%
Beta
0.33
Analyst Price Targets
Based on analyst covering MGRO
Wall Street analysts forecast MGRO stock price to rise 610.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.70
+610.5% Upside
Current Price
C$0.38
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MGRO's historical volatility
30-Day Vol
66.7%
Annualized
90-Day Vol
70.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.36 | C$0.28 – C$0.45 |
| 60 trading days | C$0.34 | C$0.24 – C$0.47 |
| 90 trading days | C$0.32 | C$0.21 – C$0.47 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Earnings Estimate Signals Ongoing Challenges for MustGrow
With an EPS estimate of -CA$0.02, MustGrow's upcoming earnings report reflects persistent losses, highlighting the need for a turnaround strategy as the company seeks to capitalize on recent product approvals and market expansions.
Bull case
- The approval of TerraSante™ in Georgia could open new revenue streams, boosting growth potential.
- Recent market awareness initiatives may help improve investor confidence and engagement.
- Positive results from canola field trials suggest the product could be effective, potentially driving sales.
Bear case
- The company has a negative profit margin of -82.77%, showing ongoing financial challenges.
- The closure of NexusBioAg raises concerns about its market presence and distribution capabilities in Canada.
- With a forward P/E of 0x, the lack of earnings might deter potential investors.
Strategic Moves Amid Financial Losses
MustGrow Biologics Corp. has been navigating a tough financial landscape, with a reported EPS of -CA$0.13 over the last twelve months. The decision to close its Canadian distribution arm, NexusBioAg, signals a shift towards focusing on the U.S. market, especially with the recent approval of its TerraSante™ biofertility product. This could indicate a long-term strategy to boost revenue despite current losses.
Market Response to Recent Developments
The market's reaction to MustGrow's recent announcements, including the TerraSante™ product approval, will be crucial in assessing investor sentiment. While the company has faced challenges, such as a high P/B ratio of 35.52x, the potential for growth in the U.S. market could provide a much-needed boost if the earnings report shows positive movement.
What to Watch in the Earnings Report
Investors should pay close attention to MustGrow's revenue figures and any guidance for future quarters. Given the backdrop of significant operational changes and product approvals, insights into sales growth and market strategy will be key in shaping investor expectations moving forward.
Advertisement
